-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike★How is the protective effect of mRNA vaccines against mutant strains? The latest data gives all-round answersYiMike broke the news★Bangyao Biotech appointed Ms.
Li Fuying as Vice President & Head of the Pharmaceutical Affairs DepartmentYiMike broke the news.
Click on the picture and sign up now September 29, 2021 / YiMike News eMedClub PR News/--Recently, WuXi Genuo BCMA targeting autologous CAR-T drug JWCAR-T was approved clinically for relapsed/refractory multiple myeloma (R/R MM)
.
This is the second CAR-T product of WuXi Ju Nuo.
Previously, WuXi Ju Nuo marketed CD19 CAR-T Regi Olenza (JWCAR029) for the treatment of relapsed or refractory large B-cell lymphoma ;Rigid Oronza is the second CAR-T therapy approved for marketing after Fosun Kate Akielon (trade name: Yikaida)
.
In addition to the above two CAR-T therapies, WuXi Junuo also has a second-generation CD19 CAR-T therapy Nex-G in its pipeline
.
This shows that the CAR-T market has great potential, and we look forward to the relevant data of WuXi Junuo in CAR-T cell therapy in the future
.
Recommended reading: China's first Class 1 CAR-T new drug! WuXi Giant Noreki Orendx is about to be launchedYimai Meng broke the news to explore the treatment of multiple myeloma.
Multiple myeloma (MM) is the second most common hematological malignant tumor after non-Hodgkin's lymphoma
.
In this disease, clonal plasma cells in the bone marrow deteriorate and abnormally proliferate.
Malignant plasma cells can replace normal blood cells in the body, leading to anemia and uncontrollable bleeding
.
It can also cause bone density and strength problems, and increase the risk of infection by reducing the body's immune response
.
In recent years, despite great progress in chemotherapy, proteasome inhibitors, and immunomodulator thalidomide derivatives, almost all patients will eventually relapse
.
Therefore, the treatment of this disease is still in urgent need of new treatment options
.
CAR-T cell immunotherapy (chimeric antigen receptor T cell immunotherapy) is currently one of the most disruptive emerging technologies in the field of tumor treatment.
Compared with other tumor treatment methods, such as surgical resection, radiotherapy and chemotherapy, small molecules Targeted drugs, monoclonal antibodies, and hematopoietic stem cell transplantation have many advantages such as more "precision", more "flexible", "broad-spectrum", and "durable"
.
Among the CAR-T drugs approved by the FDA in the world, only the Bristol-Myers Squibb (BMS)/Bluebird targeting BCMA CAR-T cell product Abecma (idecabtagene vicleucel; ide-cel), which was launched in March this year, has been used for treatment.
Adult patients with relapsed/refractory multiple myeloma (r/r MM) with more than four previous treatments
.
At present, in the treatment of multiple myeloma, many companies and scientists try to treat the disease from various angles, such as antibody drugs, dual-target CAR-T cell therapy, NK cell therapy and other drugs
.
In July 2021, Johnson & Johnson's Janssen Company announced that the US Food and Drug Administration (FDA) approved the anti-CD38 monoclonal antibody Darzalex Faspro combined with pomalidomide and dexamethasone for second-line treatment Adult patients with multiple myeloma
.
Recommended reading: Innovative subcutaneous drug delivery! Johnson & Johnson's CD38 monoclonal antibody combination therapy for the second-line treatment of multiple myelomaYimai Meng broke the news in July 2021, XNK Therapeutics announced that the Phase II clinical study of its autologous natural killer (NK) cell therapy candidate CellProtect has been included in the first patient.
The drug is combined with Sanofi's anti-CD38 antibody Sarclisa (Isatuximab) to treat patients with multiple myeloma
.
Recommended reading: NK cells combined with CD38 antibody to treat multiple myelomaYi Mai Meng broke the news on May 21, 2021, Genxi Biotechnology Group, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and 2021 European Hematology During the conference of the Association (EHA), the latest clinical research results of a multi-center, first human trial of GC012F in the treatment of relapsed/refractory multiple myeloma were published
.
GC012F is a BCMA/CD19 dual-targeting autologous CAR-T cell therapy developed based on the FasTCAR patented technology platform of Genxi Biotech
.
It has the advantage of "production can be completed the next day" .
Recommended reading: ASCO&EHA | Genxi Bio will announce the latest results of the BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in the treatment of relapsed or refractory multiple myeloma.
The CAR-T treatment market has continued to expand for nearly two years.
CAR-T is on the market.
Globally, more and more companies are making efforts in the CAR-T field, and the number of clinical trials of CAR-T therapy is also increasing
.
The target determines the direction of the indications.
In terms of indications, CAR-T cell immunity shows good targeting, killing and durability in the treatment of hematological tumors
.
The development of solid tumors has been relatively slow due to many reasons.
On the one hand, the characteristics of solid tumors and hematological tumors are very different.
The high degree of difference makes the treatment of CAR-T therapy in solid tumors more difficult
.
On the other hand, solid tumors are not only expressed in tumor tissues in tumor antigens, but also expressed in normal tissues, which leads to reduced CAR-T recognition
.
There are dozens of design targets for CAR-T projects under clinical research
.
However, from the perspective of popular research on targets, CAR-T cell therapy clinical trials are mainly concentrated in popular areas such as CD19, CD20, CD22, GPC3, and BCMA
.
Among them, among the CAR-T therapies approved by the FDA, four of them are CAR-T cell products targeting CD19, namely Novartis’ Kymriah, Gilead’s subsidiary Kite Pharmaceutical’s Yescarta and Tecartus, and BMS’s CAR-T.
Cell product Liso-cel, only BMS’s CAR-T cell product Abecma’s target is BCMA.
The approval of Abecma is a milestone breakthrough in CAR-T cell therapy, marking that the commercialization track of BCMA CAR-T has officially opened.
.
The important feature of B cell maturation antigen (BCMA) is that it is highly expressed on MM cells and not expressed in other normal tissues (except plasma cells).
Therefore, BCMA has become a number of companies and research institutions to develop MM and other hematological malignancies immunotherapy Popular targets for strategies
.
In the future, with the discovery of more targets and the clarification of the mechanism of action, as well as the development of related clinical trials, the application of CAR-T in solid tumors has broader development prospects
.
In the "BPID 2021 Shanghai (Minhang) Biomedicine Industry Innovation Summit" held from October 11th to 12th, IMC invited many industry experts to discuss cutting-edge innovations in biomedicine, focusing on hot spots such as innovative technologies, processes, and industrial investment strategies.
Topic, hold a wonderful academic conference, click to read the original text to sign up! Disclaimer: The content in this article is only used to explore the cutting-edge progress of biomedicine and does not constitute any medical guidance.
If you need it, please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
Li Fuying as Vice President & Head of the Pharmaceutical Affairs DepartmentYiMike broke the news.
Click on the picture and sign up now September 29, 2021 / YiMike News eMedClub PR News/--Recently, WuXi Genuo BCMA targeting autologous CAR-T drug JWCAR-T was approved clinically for relapsed/refractory multiple myeloma (R/R MM)
.
This is the second CAR-T product of WuXi Ju Nuo.
Previously, WuXi Ju Nuo marketed CD19 CAR-T Regi Olenza (JWCAR029) for the treatment of relapsed or refractory large B-cell lymphoma ;Rigid Oronza is the second CAR-T therapy approved for marketing after Fosun Kate Akielon (trade name: Yikaida)
.
In addition to the above two CAR-T therapies, WuXi Junuo also has a second-generation CD19 CAR-T therapy Nex-G in its pipeline
.
This shows that the CAR-T market has great potential, and we look forward to the relevant data of WuXi Junuo in CAR-T cell therapy in the future
.
Recommended reading: China's first Class 1 CAR-T new drug! WuXi Giant Noreki Orendx is about to be launchedYimai Meng broke the news to explore the treatment of multiple myeloma.
Multiple myeloma (MM) is the second most common hematological malignant tumor after non-Hodgkin's lymphoma
.
In this disease, clonal plasma cells in the bone marrow deteriorate and abnormally proliferate.
Malignant plasma cells can replace normal blood cells in the body, leading to anemia and uncontrollable bleeding
.
It can also cause bone density and strength problems, and increase the risk of infection by reducing the body's immune response
.
In recent years, despite great progress in chemotherapy, proteasome inhibitors, and immunomodulator thalidomide derivatives, almost all patients will eventually relapse
.
Therefore, the treatment of this disease is still in urgent need of new treatment options
.
CAR-T cell immunotherapy (chimeric antigen receptor T cell immunotherapy) is currently one of the most disruptive emerging technologies in the field of tumor treatment.
Compared with other tumor treatment methods, such as surgical resection, radiotherapy and chemotherapy, small molecules Targeted drugs, monoclonal antibodies, and hematopoietic stem cell transplantation have many advantages such as more "precision", more "flexible", "broad-spectrum", and "durable"
.
Among the CAR-T drugs approved by the FDA in the world, only the Bristol-Myers Squibb (BMS)/Bluebird targeting BCMA CAR-T cell product Abecma (idecabtagene vicleucel; ide-cel), which was launched in March this year, has been used for treatment.
Adult patients with relapsed/refractory multiple myeloma (r/r MM) with more than four previous treatments
.
At present, in the treatment of multiple myeloma, many companies and scientists try to treat the disease from various angles, such as antibody drugs, dual-target CAR-T cell therapy, NK cell therapy and other drugs
.
In July 2021, Johnson & Johnson's Janssen Company announced that the US Food and Drug Administration (FDA) approved the anti-CD38 monoclonal antibody Darzalex Faspro combined with pomalidomide and dexamethasone for second-line treatment Adult patients with multiple myeloma
.
Recommended reading: Innovative subcutaneous drug delivery! Johnson & Johnson's CD38 monoclonal antibody combination therapy for the second-line treatment of multiple myelomaYimai Meng broke the news in July 2021, XNK Therapeutics announced that the Phase II clinical study of its autologous natural killer (NK) cell therapy candidate CellProtect has been included in the first patient.
The drug is combined with Sanofi's anti-CD38 antibody Sarclisa (Isatuximab) to treat patients with multiple myeloma
.
Recommended reading: NK cells combined with CD38 antibody to treat multiple myelomaYi Mai Meng broke the news on May 21, 2021, Genxi Biotechnology Group, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and 2021 European Hematology During the conference of the Association (EHA), the latest clinical research results of a multi-center, first human trial of GC012F in the treatment of relapsed/refractory multiple myeloma were published
.
GC012F is a BCMA/CD19 dual-targeting autologous CAR-T cell therapy developed based on the FasTCAR patented technology platform of Genxi Biotech
.
It has the advantage of "production can be completed the next day" .
Recommended reading: ASCO&EHA | Genxi Bio will announce the latest results of the BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in the treatment of relapsed or refractory multiple myeloma.
The CAR-T treatment market has continued to expand for nearly two years.
CAR-T is on the market.
Globally, more and more companies are making efforts in the CAR-T field, and the number of clinical trials of CAR-T therapy is also increasing
.
The target determines the direction of the indications.
In terms of indications, CAR-T cell immunity shows good targeting, killing and durability in the treatment of hematological tumors
.
The development of solid tumors has been relatively slow due to many reasons.
On the one hand, the characteristics of solid tumors and hematological tumors are very different.
The high degree of difference makes the treatment of CAR-T therapy in solid tumors more difficult
.
On the other hand, solid tumors are not only expressed in tumor tissues in tumor antigens, but also expressed in normal tissues, which leads to reduced CAR-T recognition
.
There are dozens of design targets for CAR-T projects under clinical research
.
However, from the perspective of popular research on targets, CAR-T cell therapy clinical trials are mainly concentrated in popular areas such as CD19, CD20, CD22, GPC3, and BCMA
.
Among them, among the CAR-T therapies approved by the FDA, four of them are CAR-T cell products targeting CD19, namely Novartis’ Kymriah, Gilead’s subsidiary Kite Pharmaceutical’s Yescarta and Tecartus, and BMS’s CAR-T.
Cell product Liso-cel, only BMS’s CAR-T cell product Abecma’s target is BCMA.
The approval of Abecma is a milestone breakthrough in CAR-T cell therapy, marking that the commercialization track of BCMA CAR-T has officially opened.
.
The important feature of B cell maturation antigen (BCMA) is that it is highly expressed on MM cells and not expressed in other normal tissues (except plasma cells).
Therefore, BCMA has become a number of companies and research institutions to develop MM and other hematological malignancies immunotherapy Popular targets for strategies
.
In the future, with the discovery of more targets and the clarification of the mechanism of action, as well as the development of related clinical trials, the application of CAR-T in solid tumors has broader development prospects
.
In the "BPID 2021 Shanghai (Minhang) Biomedicine Industry Innovation Summit" held from October 11th to 12th, IMC invited many industry experts to discuss cutting-edge innovations in biomedicine, focusing on hot spots such as innovative technologies, processes, and industrial investment strategies.
Topic, hold a wonderful academic conference, click to read the original text to sign up! Disclaimer: The content in this article is only used to explore the cutting-edge progress of biomedicine and does not constitute any medical guidance.
If you need it, please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
